Research programme: allergy prophylaxis - Protectimmun

Drug Profile

Research programme: allergy prophylaxis - Protectimmun

Alternative Names: Antiallergy vaccine - Protectimmun

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator Protectimmun
  • Class Allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Allergic asthma; Hypersensitivity; Seasonal allergic rhinitis

Most Recent Events

  • 05 Aug 2016 Preclinical trials in Allergic asthma (Prevention) in Germany (Intranasal)
  • 05 Aug 2016 Preclinical trials in Hypersensitivity (Prevention) in Germany (Intranasal)
  • 05 Aug 2016 Preclinical trials in Seasonal allergic rhinitis (Prevention) in Germany (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top